Growth Metrics

Cellectis (CLLS) Cash from Discontinued Operations (2022 - 2023)

Cellectis (CLLS) posted Cash from Discontinued Operations of 1000.0 for Q4 2023, up 200.0% on a QoQ basis from 1000.0 in Q3 2023, and up 100.03% year-over-year from 499.93 in Q4 2022.

Cellectis (CLLS) has 2 years of Cash from Discontinued Operations data on file, last reported at 1000.0 in Q4 2023.

  • In Q4 2023, Cash from Discontinued Operations rose 100.03% year-over-year to 1000.0; the TTM figure through Dec 2023 stood at 3644000.0 (up 80.41% YoY), while the FY2023 annual figure was 3644000.0, up 80.41% from the prior year.
  • Cash from Discontinued Operations rose to 1000.0 in Q4 2023, from 1000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 1000.0 in Q4 2023 and bottomed at 6851000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Cellectis 20.83 Bn 20.62 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 1,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 -1,000.00
Sep 30, 2023 -1,000.00
Jun 30, 2023 -1.67 Mn
Jun 30, 2023 -1.67 Mn
Mar 31, 2023 -1.97 Mn
Mar 31, 2023 -1.97 Mn
Dec 31, 2022 -3.47 Mn
Dec 31, 2022 -3.47 Mn
Sep 30, 2022 -3.16 Mn
Sep 30, 2022 -3.16 Mn
Jun 30, 2022 -5.12 Mn
Jun 30, 2022 -5.12 Mn
Mar 31, 2022 -6.85 Mn
Mar 31, 2022 -6.85 Mn